— Senior leaders to provide insight into TerrAscend’s recent success and growth potential

TORONTO, April 12, 2019 – Senior executives from TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend”), a leading North American Operator with a strong presence across the entire cannabis value chain, will attend GMP Securities’ 2019 Cannabis Conference to be held April 16, 2019 at the Ritz-Carlton Hotel in Toronto.

TerrAscend President Matthew Johnson will share highlights of TerrAscend’s strategy and operations, including plans for expansion through organic growth, acquisitions, and partnerships in North America and globally. He will present at 3PM EDT in the Ritz-Carlton Ballroom.

For more information, please reach out to the TerrAscend investor relations team: IR@terrascend.com.

About TerrAscend

TerrAscend is a biopharmaceutical and wellness company that is committed to quality products, brands, and services for the global cannabinoid market. The Company participates in the medical and legal adult-use market in Canada and in US states where cannabis has been legalized for therapeutic or adult-use. TerrAscend operates a number of synergistic businesses, including Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products, Ascendant Laboratories Inc., a biotechnology and licensing Company committed to the continuous improvement of cannabinoid expressing plants, and Solace RX Inc., a proposed drug preparation premises focused on the development of novel formulations and dosage forms.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States.  Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to cultivate, distribute or possess cannabis in the United States.  Furthermore, financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under US federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend.  Following any investment made by TerrAscend in operations in the United States, enforcement of federal laws in the United States will be a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.